Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from the EuroSpA Research Collaboration Network.

Hellamand, Pasoon; van de Sande, Marleen G H; Ørnbjerg, Lykke M; Klausch, Thomas; Eklund, Kari K; Relas, Heikki; Santos, Maria J; Vieira-Sousa, Elsa; Loft, Anne G; Glintborg, Bente; Østergaard, Mikkel; Lindström, Ulf; Wallman, Johan K; Michelsen, Brigitte; Fagerli, Karen M; Castrejón, Isabel; Gudbjornsson, Bjorn; Love, Thorvardur J; Vencovský, Jiří; Nekvindová, Lucie; ... (2024). Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from the EuroSpA Research Collaboration Network. Arthritis & rheumatology, 76(4), pp. 587-598. Wiley-Blackwell 10.1002/art.42758

Text Arthritis_Rheumatology_-_2023_-_Hellamand_-_Sex_differences_in_the_effectiveness_of_first_line_tumor_necrosis_factor.pdf - Accepted Version Restricted to registered users only until 16 November 2024. Available under License Publisher holds Copyright. Download (2MB) | Request a copy

OBJECTIVE

Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi.

METHODS

Data from PsA patients across 13 EuroSpA registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response, using low disease activity (LDA) according to DAS28-CRP (<3.2) at 6 months as the primary outcome. Analyses were adjusted for age, country, csDMARD use, and TNFi start year. Retention rates were explored using the Kaplan-Meier estimators.

RESULTS

We analyzed the treatment response of 7,679 PsA patients (50% women) with available data on LDA at 6 months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs. men, 4.4 [SD 1.2] vs. 4.2 [1.2]), though patient-reported outcome measures were worse in women. At 6 months, 64% of women and 78% of men had LDA (relative risk, 0.82; 95% confidence interval, 0.80 to 0.84). This difference was similar after adjustment (0.83; 0.81 to 0.85). TNFi retention rates were evaluated in 17,842 PsA patients. Women had significantly lower retention rates than men at all time points (women: 79%/64%/50% at 6/12/24 months versus men: 88%/77%/64%).

CONCLUSION

Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.

Interest & Impact

Downloads

0 since deposited on 20 Nov 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item